Slc3a2-KO 基因敲除小鼠

1. Liu, Hailong, Deng, Zengfa, Yu, Baoxi, Zeng, Anyu, Fu, Ming. 2022. Identification of SLC3A2 as a Potential Therapeutic Target of Osteoarthritis Involved in Ferroptosis by Integrating Bioinformatics, Clinical Factors and Experiments. In Cells, 11, . doi:10.3390/cells11213430. https://pubmed.ncbi.nlm.nih.gov/36359826/

2. Xu, Yuheng, Weng, Wanqi, Weng, Yuhao, Wang, Zhaotao, Zhang, Shizhen. 2024. Elevated SLC3A2 associated with poor prognosis and enhanced malignancy in gliomas. In Scientific reports, 14, 15758. doi:10.1038/s41598-024-66484-1. https://pubmed.ncbi.nlm.nih.gov/38977800/

3. Wang, Binyang, Fu, Chenyang, Wei, Yuanyuan, Yin, Yong, Qin, Dongdong. 2022. Ferroptosis-related biomarkers for Alzheimer's disease: Identification by bioinformatic analysis in hippocampus. In Frontiers in cellular neuroscience, 16, 1023947. doi:10.3389/fncel.2022.1023947. https://pubmed.ncbi.nlm.nih.gov/36467613/

4. Wu, Fangxing, Xiong, Gaoyun, Chen, Zejun, Liu, Qianqian, Bai, Yundan. 2022. SLC3A2 inhibits ferroptosis in laryngeal carcinoma via mTOR pathway. In Hereditas, 159, 6. doi:10.1186/s41065-022-00225-0. https://pubmed.ncbi.nlm.nih.gov/35057861/